The Efficacy of Duvelisib Monotherapy Following Disease Progression on Ofatumumab Monotherapy in Patients with Relapsed/Refractory CLL or SLL in the DUO™ Crossover Extension Study

Bryone Kuss, Matthew S. Davids, Peter Hillmen, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Ulrich Jaeger, Constantine Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Diep Le, Brenda Jeglinksi, Marco Montillo

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Background: Duvelisib, an oral dual inhibitor of PI3K-δ,γ, is being developed for the treatment of hematologic malignancies, including relapsed/refractory (RR) CLL/SLL. In the Phase 3 DUO study (NCT02004522) duvelisib monotherapy demonstrated significant improvement compared to ofatumumab monotherapy (PFS 13.3 vs 9.9 mo. p < 0.0001; ORR 74% vs 45% p < 0.0001) with a manageable safety profile (Flinn, ASH 2017). Study IPI-145-12 (NCT02049515) is an open-label, optional, crossover extension study where pts with confirmed progressive disease (PD) on DUO were given the option to receive the opposite treatment. Herein we present data for the 89 pts who voluntarily rolled over following PD on ofatumumab on DUO and received duvelisib on Study IPI-145-12.
Original languageEnglish
Article number7533
Number of pages1
JournalJournal of Clinical Oncology
Volume36
Issue numberS15
Publication statusPublished - 20 May 2018
Externally publishedYes
Event2018 American Society for Clinical Oncology Annual Meeting - Chicago, United States
Duration: 1 Jun 20185 Jun 2018

Keywords

  • Duvelisib Monotherapy
  • Ofatumumab Monothapy
  • Relapsed/Refractory CLL

Fingerprint

Dive into the research topics of 'The Efficacy of Duvelisib Monotherapy Following Disease Progression on Ofatumumab Monotherapy in Patients with Relapsed/Refractory CLL or SLL in the DUO™ Crossover Extension Study'. Together they form a unique fingerprint.

Cite this